Author(s): Johannes Hertelendy, Georg Reumuth, David Simons, Christian Stoppe, Bong-Sung Kim, Jan-Philipp Stromps, Paul C. Fuchs, Jurgen Bernhagen, Norbert Pallua and Gerrit Grieb*
Page: [601 - 605] Pages: 5
* (Excluding Mailing and Handling)
Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.
Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.
Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.
Keywords: MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.
Download PDF Flyer